Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary Shares

REHOVOT, Israel and BRIDGEWATER, N.J., Sept. 27, 2016 /PRNewswire/ -- Foamix Pharmaceuticals Ltd. ("Foamix") (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing its proprietary topical foams to address unmet needs in dermatology, today announced that it intends to commence an underwritten public offering of its ordinary shares. A portion of the shares will be sold by certain selling shareholders. Foamix also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering on the same terms and conditions.

Barclays Capital Inc., Credit Suisse Securities (USA) LLC and Cowen and Company, LLC are acting as joint book-running managers for the proposed offering. Guggenheim Securities, LLC is acting as lead manager.

A shelf registration statement relating to these securities has been filed with the Securities and Exchange Commission ("SEC") and was declared effective on September 23, 2016. A preliminary prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to these securities may also be obtained, when available, from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1(888)603-5847, email: [email protected]; Credit Suisse Securities (USA) LLC, Attention: Prospectus Department, One Madison Avenue, New York, NY 10010, telephone: (800)221-1037, email: [email protected]; or Cowen and Company, LLC, c/o Broadridge Financial Services, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: (631)274-2806, fax: (631)254-7140. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Foamix Pharmaceuticals Ltd.

Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological conditions.

Our clinical stage product candidates include FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne, FMX103 for the treatment of moderate-to-severe rosacea, FMX102 for the treatment of impetigo and FDX104, our doxycycline foam for the management of acne-like rash induced by EGFRI anticancer drugs.

Forward-Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the U.S. Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions, expectations, forecasts, beliefs or intentions related to financial results, commercial results, timing and results of clinical trials and U.S. FDA and other regulatory agencies authorizations.  Forward-looking statements are based on our current knowledge and our present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions.  We discuss many of these risks in greater detail under the heading "Risk Factors" in our most recent Annual Report on Form 20-F (File No. 001-36621) filed on March 2, 2016, and elsewhere in that Annual Report. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.

Logo - http://photos.prnewswire.com/prnh/20160906/404614LOGO

Contact
Ilan Hadar
CFO
Foamix Pharmaceuticals Ltd.
+972-8-9316233
[email protected]

U.S. Investor Relations
Michael Rice
LifeSci Advisors, LLC
+1-646-597-6979
[email protected]

SOURCE Foamix Pharmaceuticals Ltd.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED